Best Cardiac and Vascular Disorders Companies in Texas, United States
The 65 best Cardiac and Vascular Disorders companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Procyrion.
Ranked: Best Cardiac and Vascular Disorders companies in Texas
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Procyrion Developing percutaneous mechanical circulatory support for heart failure and cardiorenal syndrome | $114M | 28 mo ago | 28 | Eric Fain President and CEO | Series E | — | 100 patents Percutaneous intravascular blood pumps for mechanical circulatory support and perfusion. | — |
| 2 | Alleviant Medical Developer of devices to lift the burden of heart failure | $89M | 16 mo ago | 37 | Jacob Kriegel Md Co-Founder & CMO | Series C | Top 50M | — | — |
| 3 | Encysive Pharmaceuticals Endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. | $89M | 226 mo ago | 148 | — | Acquired | — | 173 patents Design of propionic-acid-based integrin-binding inhibitor compounds. | — |
| 4 | Idev Technologies Self expanding stent system | $59M | 171 mo ago | 54 | Soumya Pratihari Founder | Acquired | — | 64 patents Medical device technologies for stent delivery systems and strand‑end securing mechanisms | — |
| 5 | BiO2 Medical Innovating medical devices and biotechnology solutions for critical care and research | $56M | 110 mo ago | 17 | — | Series D | — | 143 patents Implantable vena cava filtration and catheter systems for intravascular blood clot management | — |
| 6 | On-X Life Technologies Heart valve replacement and repair products | $32M | 227 mo ago | 140 | — | Acquired | Top 50M | 8,315 patents Advanced fluorescent labeling and high-throughput nucleic acid diagnostic assays | — |
| 7 | Saranas Developer of a device for the detection of internal bleeding during catheterization | $29M | 59 mo ago | 22 | — | Series B | — | 43 patents Vascular access closure devices with real-time bleed detection via bioimpedance monitoring | — |
| 8 | Bivacor Developer of ventricular assist device (VAD) | $28M | 23 mo ago | 29 | — | Series B | Top 5M | 45 patents Design and control of ventricular assist blood pumps and heart pump drive systems | 1 job opening |
| 9 | MicroMed Technology Developer of axial flow pump for congestive heart failure | $28M | 252 mo ago | 15 | Dallas Anderson Co-Founder | Series A | — | 45 patents Implantable blood pump and ventricular assist device flow measurement and calibration systems | — |
| 10 | TVA Medical Minimally invasive therapies for renal disease | $27M | 114 mo ago | 20 | — | Acqui-Hired | — | 194 patents Dialysis vascular access: catheter systems for creating and treating arteriovenous fistulas | — |
| 11 | Secretome Therapeutics Developer of cell-based therapies for multiple diseases | $22M | 0 mo ago | 8 | Sudhish Sharma Co-Founder | Series A | Top 10M | — | — |
| 12 | CeloNova BioSciences Innovating biocompatible coatings for medical devices, enhancing safety and performance | $21M | 106 mo ago | 52 | — | Acquired | — | 125 patents Design and manufacturing of implantable expandable stents, including drug‑eluting cardiovascular devices. | — |
| 13 | Adient Medical Provider of bio-absorbable medical devices | $19M | 48 mo ago | 6,421 | — | Series B | — | — | — |
| 14 | Fourth Frontier Provider of a connected wearable device for cardiac health monitoring | $15M | 59 mo ago | 48 48 → 76 (+58%) | Manav Bhushan Co-Founder & Co-CEO | Series B | Top 5M | — | 5 job openings |
| 15 | Cellvie Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney… | $10M | 9 mo ago | 12 | Alexander Schueller Founder & CEO | Seed | Top 50M | 10 patents Optimizing manufacturing and potency of adoptive immune cell therapies | — |
| 16 | BioStable Aortic valve repair solutions: simplifying, standardizing, and restoring valve function | $10M | 76 mo ago | 4 | — | Series A | — | — | 2 launchs |
| 17 | Bluegrass Vascular Innovating lifesaving vascular access solutions, restoring vein access and improving patient outcomes | $10M | 51 mo ago | 11 | — | Series A | — | — | — |
| 18 | Corvion Developer of an implanted mechanical circulatory support device for heart failure | $10M | 16 mo ago | 5 | Greg Aber Founder & CEO | Series A | — | 14 patents Advanced high-efficiency ventricular assist devices for cardiac support | — |
| 19 | Renovo Concepts Developer of a mechanical tissue resuscitation system for the treatment of traumatic, ischemic, and… | $9M | 38 mo ago | 5 | Charles Biltz Co-Founder | Series A | — | 9 patents Medical negative-pressure wound therapy devices and biocompatible porous biomaterials. | — |
| 20 | CMI Holding Manufacturer of surgical ventricular restoration systems | $9M | 195 mo ago | 22 | Albert Davis CEO | Series A | Top 50M | — | — |
| 21 | HeartSciences Provider of a screening device for the early detection of cardiac dysfunction | $8M | 31 mo ago | 12 12 → 23 (+92%) | Mark Hilz CEO | Public | Top 5M | 3 patents Non‑invasive ECG algorithms estimating echocardiographic cardiac function metrics | 3 launchs · 1 partnership |
| 22 | Autonomix Developer of minimally invasive neural monitoring and treatment devices | $8M | 36 mo ago | 4 | Robert Schwartz Co-Founder | Public | Top 50M | — | 1 launch |
| 23 | Admittance Technologies Algorithm based system for heart volume determination | $6M | 102 mo ago | 3 | Marc D Feldman Founder | Deadpooled | — | 12 patents Cardiac hemodynamic monitoring and bi‑ventricular pacemaker tuning using admittance measurement | — |
| 24 | Corhythm Drug device combination for atrial fibrillation | $4M | 185 mo ago | — | — | Seed | — | — | — |
| 25 | Guidepath Medical Developer of a portfolio of vascular devices | $1M | 203 mo ago | — | — | Deadpooled | — | — | — |
| 26 | Affirmed Pharma Translational drug development company specializing in late-stage therapeutics | $1M | 15 mo ago | — | John Weatherspoon Co-Founder | Funding Raised | — | — | — |
| 27 | Windmill Cardiovascular Systems Developing revolutionary blood pump technology for heart failure treatment | $920K | 165 mo ago | 10 | Raul Longoria Co-Founder | Seed | — | — | — |
| 28 | PolyVascular Developer of valve to treat congenital heart disease | $795K | 33 mo ago | 9 | Tim Smokoff CEO | Seed | — | — | — |
| 29 | BioLum Sciences Innovative chemiluminescence solutions for drug discovery and early disease detection | $729K | 54 mo ago | 4 | — | Series A | — | — | — |
| 30 | Foment Bio Developer of non-viral, off-the-shelf gene therapies for tissue repair | $543K | 24 mo ago | — | Marc Penn Co-Founder & CBO | Seed | — | — | — |
| 31 | SageSpectra Developer of a medical device for the detection of peripheral artery disease | $350K | 20 mo ago | 4 | Madi Heck CEO | Funding Raised | — | — | — |
| 32 | Corveus Medical Provider of neuromodulation device to prevent heart failure | $125K | 39 mo ago | 4 | Ishan Kamat CMO & Co-Founder | Seed | — | — | — |
Top 12 Cardiac and Vascular Disorders companies in Texas
#1
Series A · Dallas, Texas · founded 2018 · 8 employees$22.1Mraised▾
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
- Mar 2026Series B$250K
- Nov 2024Series B$20.4M
- Oct 2019Seed$1.5M
#2
Series C · Houston, Texas · founded 2017 · 37 employees$89.1Mraised▾
Developer of devices to lift the burden of heart failure. . The company has developed a transcatheter technology intended to decompress the left atrium without a permanent cardiac implant or open surgery. The procedure is performed under fluoroscopy (x-ray) and ultrasound guidance using a minimally-invasive approach and leverages standard interventional cardiology techniques.
- Feb 2025Grant (prize money)$3.9M
- Feb 2025Grant (prize money)$3.9M
- Dec 2024Series C$90.8M
- Sep 2024Grant (prize money)$499.1K
#3
Seed · Houston, Texas · founded 2020 · 12 employees$10.5Mraised▾
Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney transplantation. The company has developed cell-based medicines by using the therapeutic potential of mitochondria. Its proprietary technology generates chemical energy by using the cell's biochemical reactions that help in the treatment of ischemia-reperfusion injury or reoxygenation injury.
- Sep 2025Seed$5M
- Feb 2023Seed$5.5M
- Jan 2021Seed$5M
- Sep 2020Grant (prize money)—
#4
Series B · Houston, Texas · founded 2008 · 29 employees$28Mraised▾
Developer of ventricular assist device (VAD). It is a compact device that uses rotary blood pump technology to provide the required cardiac output. It comprises a magnetically levitated rotor located between opposing pump casings. An external controller and batteries provide power to the internal device via a percutaneous driveline.
- Jul 2024Series B$9M
- Feb 2024Grant (prize money)$13M
- Aug 2023Grant (prize money)$1.6M
- Aug 2021Grant (prize money)$2M
#5
Series A · Webster, Texas · founded 2012 · 5 employees$9.5Mraised▾
Developer of an implanted mechanical circulatory support device for heart failure. The company's Left Ventricular Assist Device has an implantable centrifugal rotary blood pump, with transcutaneous wireless charging technology that helps in cardiac support.
- Feb 2025Grant (prize money)$1M
- Feb 2023Series A$917.5K
- Feb 2022Grant (prize money)$428.2K
- Feb 2020Series A$8.6M
#6
Series E · Houston, Texas · founded 2005 · 28 employees$114.3Mraised▾
Developing percutaneous mechanical circulatory support for heart failure and cardiorenal syndrome. This company is dedicated to addressing the unmet clinical needs of heart failure patients. It focuses on the research and development of a safe and innovative percutaneous mechanical circulatory support (pMCS) device, Aortix™. This technology aims to reduce cardiac workload and increase renal perfusion, disrupting the cardiorenal syndrome cycle. The device is designed for percutaneous deployment and is currently in the investigational phase, exclusively for clinical investigations. The company is comprised of experienced life science entrepreneurs, engineers, cardiologists, and heart failure specialists. This innovative approach has the potential to change the way patients with acute decompensated heart failure and cardiorenal syndrome are treated.
- Feb 2024Series E$57.7M
- Jul 2019Series D$30M
- Jan 2018Series C$16M
- Jul 2015Series B$10M
#7
Funding Raised · Conroe, Texas · founded 2019$1.1Mraised▾
Translational drug development company specializing in late-stage therapeutics. It transitions late-stage development drugs to high-value therapeutics, coordinating investigational, regulatory, intellectual property, and commercialization strategies. The company targets therapies in late-stage pre-clinical or early clinical development at research organizations and universities, leveraging in-house patent evergreening strategies. Their clinical focus includes regenerative medicine, cancer immunotherapies, and cardiovascular disease interventions.
- Mar 2025Grant (prize money)$388.2K
- Sep 2023Grant (prize money)$341.3K
- Feb 2022Grant (prize money)$388.8K
#8
Public · Austin, Texas · founded 2007 · 12 employees$8.2Mraised▾
Provider of a screening device for the early detection of cardiac dysfunction. The company has Continuous Wavelet Transform signal processing technology for developing MyoVista cardiac testing device to detect abnormalities of heart function. It provides doctors with a visual description of a cardiac cycle’s energy distribution.
- Nov 2023Post IPO$1.6M
- Sep 2023Post IPO$1M
- Feb 2021Conventional Debt$1.1M
- Nov 2019Series A$138K
#9
Series B · Pearland, Texas · founded 2012 · 6421 employees$19.4Mraised▾
Adient Medical is developing bioabsorbable medical devices that disappear without intervention after its usage. It is currently focused on developing a vascular filter for the prevention of pulmonary embolism. The company is using new polymers for the development of these medical devices which exhibit exceptional strength and imaging characteristics.
- Jun 2022Series B$14.3M
- Feb 2021Series A$711K
- Jan 2018Seed—
- Jul 2017Seed$1.7M
#10
Series A · San Antonio, Texas · founded 2017 · 5 employees$9.3Mraised▾
Developer of a mechanical tissue resuscitation system for the treatment of traumatic, ischemic, and hemorrhagic injuries in the brain, heart, and spinal cord. The Mechanical Tissue Resuscitation system (MTR) consists of a disposable sub-atmospheric pressure pump for controlled application of sub-atmospheric pressure for treating traumatic brain injury.
- Apr 2023Series A$7.4M
- May 2022Series A$420.1K
- Jun 2021Series A$6.4M
- May 2020Seed$1.3M
#11
Series B · Houston, Texas · founded 2011 · 22 employees$29.5Mraised▾
Developer of a device for the detection of internal bleeding during catheterization. The Early bird device is comprised of a standard cardiac sheath that is surrounded by an array of electrodes that measure the difference in electrical resistance across the blood vessel.
- Jul 2021Series B$15.5M
- May 2020Conventional Debt$1.7M
- May 2018Series B$2.8M
- May 2017Series B$4M
#12
Series D · San Antonio, Texas · founded 2006 · 17 employees$56.3Mraised▾
Innovating medical devices and biotechnology solutions for critical care and research. The company designs, develops, and manufactures advanced medical devices addressing global healthcare challenges. They combine scientific innovation with precision engineering to deliver life-saving solutions for patients and healthcare providers. Specializing in tailored biotechnology solutions, they offer support and expert guidance for research endeavors. Their primary objective is developing and commercializing medical products in response to clinical needs, including the Angel™ Catheter for pulmonary embolism prevention. They provide central venous access and clot filtration solutions, enhancing patient safety and simplifying management. The company focuses on research and development of innovative biotechnology solutions, serving the healthcare, agriculture, and environmental sectors. They offer a range of services, including consultations, product development, and research support.
- Mar 2017Series D$1.5M
- Aug 2016Conventional Debt$3M
- Mar 2016Series D$10M
- Jan 2016Conventional Debt$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.